Waldencast (WALD) Expected to Announce Earnings on Monday

Key Points

• Waldencast (WALD) is set to release its Q2 2025 earnings results on August 18th, with analysts predicting earnings of ($0.10) per share and revenue of $71.93 million.
• Waldencast's stock opened at $1.64, showing a 12-month trading range between $1.60 and $4.74, with a consensus price target of $5.11 from analysts.
• Institutional investors hold 41.97% of Waldencast's stock, with significant recent maneuvers including a 62.2% increase in holdings by Geode Capital Management.

Waldencast (NASDAQ:WALD - Get Free Report) is projected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 18th. Analysts expect Waldencast to post earnings of ($0.10) per share and revenue of $71.93 million for the quarter.

Waldencast Stock Down 2.7%

NASDAQ:WALD traded down $0.05 during trading hours on Friday, reaching $1.79. The company's stock had a trading volume of 161,355 shares, compared to its average volume of 104,078. The firm has a 50-day simple moving average of $2.26 and a 200-day simple moving average of $2.68. Waldencast has a 1 year low of $1.60 and a 1 year high of $4.74. The company has a debt-to-equity ratio of 0.21, a current ratio of 1.35 and a quick ratio of 0.66.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Telsey Advisory Group reiterated an "outperform" rating and issued a $4.00 target price on shares of Waldencast in a research report on Wednesday. Industrial Alliance Securities set a $5.00 price objective on shares of Waldencast in a research report on Tuesday, April 22nd. Alliance Global Partners restated a "buy" rating on shares of Waldencast in a research report on Thursday, May 15th. Canaccord Genuity Group decreased their price objective on shares of Waldencast from $6.00 to $5.00 and set a "buy" rating on the stock in a research report on Thursday, May 15th. Finally, Wall Street Zen cut shares of Waldencast from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $5.11.

Institutional Investors Weigh In On Waldencast

A number of large investors have recently modified their holdings of WALD. Invesco Ltd. bought a new stake in shares of Waldencast during the 2nd quarter valued at about $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Waldencast by 57.9% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,130 shares of the company's stock valued at $57,000 after purchasing an additional 8,485 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Waldencast during the 1st quarter valued at about $77,000. Rhumbline Advisers boosted its stake in shares of Waldencast by 15.2% during the 1st quarter. Rhumbline Advisers now owns 61,630 shares of the company's stock valued at $185,000 after purchasing an additional 8,151 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Waldencast by 62.2% during the 2nd quarter. Geode Capital Management LLC now owns 586,566 shares of the company's stock valued at $1,437,000 after purchasing an additional 224,905 shares in the last quarter. Institutional investors own 41.97% of the company's stock.

Waldencast Company Profile

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.